Published date: Dec 31 2024

Journal Title: Sudan Journal of Medical Sciences

Issue title: Sudan JMS: Volume 19 (2024), Issue No. 4

Pages: 531 – 546

DOI: 10.18502/sjms.v19i4.16912

Samah Elhassansam.isam97@hotmail.comNational Malaria Control Program, Federal Ministry of Health, Khartoum, Sudan

Sahar Khalid Mohamedsaharkhalidmo@gmail.comNational Malaria Control Program, Federal Ministry of Health, Khartoum, Sudan

Khlood Fathi Hassan Alnaeemsonosahar@hotmail.comNational Malaria Control Program, Federal Ministry of Health, Khartoum, Sudan

Ahmed Abdulgadir Noureddingadoura95@gmail.comDepartment of Community Medicine, College of Medicine, University of Bahri, Khartoum, Sudan

Samah Kamaleldeen Bakrri Abasssamahaakamal@gmail.comNational Malaria Control Program, Federal Ministry of Health, Sudan

Fadwa Mohamed Saadfadwamdsaad@gmail.comNational Malaria Control Program, Federal Ministry of Health, Khartoum, Sudan

Technical Advisory Committeefadwamdsaad@gmail.comSee appendix

Background: Malaria is a major public health hazard in Sudan. The latest update to the malaria diagnosis and treatment protocol in Sudan was in 2017, after which multiple developments in the global guidelines for malaria case management have taken place. Sudan’s Federal Ministry of Health (FMOH) has updated its malaria case management policy to guide healthcare workers in making informed decisions about malaria diagnosis, treatment, and prevention.
Methods: The National Malaria Control Program (NMCP) selected a multidisciplinary Technical Advisory Committee (TAC) balanced to bring together diverse expertise. The committee convened with the NMCP writing team to propose, discuss, and approve updates to the malaria case management protocol. Protocol updates were prioritized based on the guidelines’ efficacy, safety, and cost-effectiveness.
Results: The management guidelines for severe malaria were updated so that parenteral artesunate is the first-line treatment, with parenteral quinine reserved as second-line therapy. Other updates include the adoption of oral artemetherlumefantrine (AL) as the first-line treatment for uncomplicated malaria in the first trimester of pregnancy. The 2023 protocol upheld the 2017 treatment guidelines for uncomplicated malaria in other groups, including children, adults, and pregnant women in their second and third trimesters, with AL as the first-line treatment and dihydroartemisinin-piperaquine (DHAP) as the second-line treatment.
Conclusion: Key changes in the 2023 protocol include updates to the treatment guidelines for severe malaria in all patient groups and uncomplicated malaria in the first trimester of pregnancy. Future adjustments to the malaria protocol will take place in accordance with changes in the local context of Sudan as well as global malaria guidelines.

Keywords: Sudan, malaria, protocol, case management, prevention

[1] Federal Ministry of Health. (2022). Annual statistical report 2021. Federal Ministry of Health. https://drive.google.com/file/d/ 15ikYHf0hv9ECLvIDaGjB9iwUlzYdX0l7/view?usp= drive_link

[2] Adeel, A. A., Elnour, F. A. A., Elmardi, K. A., Abd- Elmajid, M. B., Elhelo, M. M., Ali, M. S., Adam, M. A., Atta, H., Zamani, G., Warsame, M., Barrette, A., Mohammady, H. E., & Nada, R. A. (2016). High efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010- 2015): Evidence from in vivo and molecular marker studies. Malaria Journal, 15(1), 285. https://doi.org/ 10.1186/s12936-016-1339-x

[3] Mohamed, A. O., Abdel Hamid, M. M., Mohamed, O. S., Elkando, N. S., Suliman, A., Adam, M. A., Elnour, F. A. A., & Malik, E. M. (2017). Efficacies of DHA-PPQ and AS/SP in patients with uncomplicated Plasmodium falciparum malaria in an area of an unstable seasonal transmission in Sudan. Malaria Journal, 16(1), 163. https://doi.org/10.1186/s12936-017- 1817-9

[4] Federal Ministry of Health. (2017). Sudan malaria treatment protocol 2017. Federal Ministry of Health. https://reliefweb.int/report/sudan/sudan-malariadiagnosis- and-treatment-protocol-2017

[5] World Health Organization. (2022). WHO guidelines for malaria, 25 November 2022. https://iris.who.int/handle/10665/364714

[6] Federal Ministry of Health. (2023). Sudan malaria case management protocol 2023. https://fmoh.gov.sd/fmoh/fmoh/public/ SudanMalariaCaseManagementProtocol2023.pdf

[7] Varo, R., Balanza, N., Mayor, A., & Bassat, Q. (2021). Diagnosis of clinical malaria in endemic settings. Expert Review of Anti-Infective Therapy, 19(1), 79– 92. https://doi.org/10.1080/14787210.2020.1807940

[8] Fitri, L. E., Widaningrum, T., Endharti, A. T., Prabowo, M. H., Winaris, N., & Nugraha, R. Y. B. (2022). Malaria diagnostic update: From conventional to advanced method. Journal of Clinical Laboratory Analysis, 36(4), e24314. https://doi.org/10.1002/jcla.24314

[9] Mukry, S. N., Saud, M., Sufaida, G., Shaikh, K., Naz, A., & Shamsi, T. S. (2017). Laboratory diagnosis of malaria: Comparison of manual and automated diagnostic tests. The Canadian Journal of Infectious Diseases & Medical Microbiology, 2017, 9286392. https://doi.org/10.1155/2017/9286392

[10] Abba, K., Deeks, J. J., Olliaro, P., Naing, C. M., Jackson, S. M., Takwoingi, Y., Donegan, S., & Garner, P. (2011). Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries. Cochrane Database of Systematic Reviews, 2011(7), CD008122.

[11] Kavanaugh, M. J., Azzam, S. E., & Rockabrand, D. M. (2021). Malaria rapid diagnostic tests: Literary review and recommendation for a quality assurance, quality control algorithm. Diagnostics, 11(5), 768. https://doi.org/10.3390/diagnostics11050768

[12] Sinclair, D., Zani, B., Donegan, S., Olliaro, P., & Garner, P. (2009). Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database of Systematic Reviews, 2009(3), CD007483. https: //doi.org/10.1002/14651858.CD007483.pub2

[13] Omari, A. A., Gamble, C. L., & Garner, P. (2005). Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Infectious Diseases Group, editor. Cochrane Database of Systematic Reviews. https://doi.wiley.com/10.1002/14651858.CD005564

[14] Adam, I., Ibrahim, Y., & Gasim, G. I. (2018). Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: A systematic review and meta-analysis. Malaria Journal, 17(1), 110. https://doi.org/10.1186/s12936-018-2265-x

[15] Zani, B., Gathu, M., Donegan, S., Olliaro, P. L., & Sinclair, D. (2014). Dihydroartemisininpiperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database of Systematic Reviews, 2014(1), CD010927. https://doi.org/10.1002/14651858.CD010927

[16] Adam, I., Salah, M. T., Eltahir, H. G., Elhassan, A. H., Elmardi, K. A., & Malik, E. M. (2010). Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Annals of Tropical Medicine and Parasitology, 104(4), 319–326. https://doi.org/10.1179/136485910X12743554760144

[17] Awab, G. R., Pukrittayakamee, S., Imwong, M., Dondorp, A. M., Woodrow, C. J., Lee, S. J., Day, N. P., Singhasivanon, P., White, N. J., & Kaker, F. (2010). Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: An openrandomized, non-inferiority, trial. Malaria Journal, 9, 105. https://doi.org/10.1186/1475-2875-9-105

[18] Phyo, A. P., Lwin, K. M., Price, R. N., Ashley, E. A., Russell, B., Sriprawat, K., Lindegardh, N., Singhasivanon, P., White, N. J., & Nosten, F. (2011). Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: A randomized controlled trial. Clinical Infectious Diseases, 53(10), 977–984. https://doi.org/10.1093/cid/cir631

[19] Kolaczinski, K., Durrani, N., Rahim, S., & Rowland, M. (2007). Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: A randomised non-inferiority trial in eastern Afghanistan. Transactions of the Royal Society of Tropical Medicine and Hygiene, 101(11), 1081–1087. https://doi.org/10.1016/j.trstmh.2007.06.015

[20] Krudsood, S., Tangpukdee, N., Muangnoicharoen, S., Thanachartwet, V., Luplertlop, N., Srivilairit, S., Wilairatana, P., Kano, S., Ringwald, P., & Looareesuwan, S. (2007). Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean Journal of Parasitology, 45(2), 111–114. https://doi.org/10.3347/kjp.2007.45.2.111

[21] Gogtay, N., Kannan, S., Thatte, U. M., Olliaro, P. L., & Sinclair, D. (2013). Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Infectious Diseases Group, editor. Cochrane Database of Systematic Reviews. https://doi.wiley.com/10.1002/ 14651858.CD008492.pub3

[22] Dondorp, A. M., Fanello, C. I., Hendriksen, I. C. E., Gomes, E., Seni, A., Chhaganlal, K. D., Bojang, K., Olaosebikan, R., Anunobi, N., Maitland, K., Kivaya, E., Agbenyega, T., Nguah, S. B., Evans, J., Gesase, S., Kahabuka, C., Mtove, G., Nadjm, B., Deen, J.,... White, N. J., & the AQUAMAT group. (2010). Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): An openlabel, randomised trial. Lancet, 376(9753), 1647– 1657. https://doi.org/10.1016/S0140-6736(10)61924-1

[23] Dondorp, A., Nosten, F., Stepniewska, K., Day, N., White, N., & the South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. (2005). Artesunate versus quinine for treatment of severe falciparum malaria: A randomised trial. Lancet, 366(9487), 717–725. https://doi.org/10.1016/S0140- 6736(05)67176-0

[24] Maka, D. E., Chiabi, A., Ndikum, V., Achu, D., Mah, E., Nguefack, S., Nana, P., Njoumemi, Z., Mbacham, W., & Mbonda, E. (2015). A randomized trial of the efficacy of artesunate and three quinine regimens in the treatment of severe malaria in children at the Ebolowa Regional Hospital, Cameroon. Malaria Journal, 14, 429. https://doi.org/10.1186/s12936-015- 0948-0

[25] Abdallah, T. M., Elmardi, K. A., Elhassan, A. H., Omer, M. B., Elhag, M. S., Desogi, M. A., Siddig, M. F., & Adam, I. (2014). Comparison of artesunate and quinine in the treatment of severe Plasmodium falciparum malaria at Kassala hospital, Sudan. Journal of Infection in Developing Countries, 8(5), 611–615. https://doi.org/10.3855/jidc.3813

[26] Okebe, J., & Eisenhut, M. (2014). Pre-referral rectal artesunate for severe malaria. Cochrane Infectious Diseases Group, editor. Cochrane Database of Systematic Reviews. http://doi.wiley.com/10.1002/ 14651858.CD009964.pub2 https://doi.org/10.1002/ 14651858.CD009964.pub2

[27] Manyando, C., Kayentao, K., D’Alessandro, U., Okafor, H. U., Juma, E., & Hamed, K. (2012). A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy. Malaria Journal, 11(1), 141. https://doi.org/10.1186/1475- 2875-11-141

[28] Kovacs, S. D., Van Eijk, A. M., Sevene, E., Dellicour, S., Weiss, N. S., Emerson, S., Steketee, R., O Ter Kuile, F., & Stergachis, A. (2016). The safety of artemisinin derivatives for the treatment of malaria in the 2nd or 3rd trimester of pregnancy: A systematic review and meta-analysis. PLoS One, 11(11), e0164963.

[29] Saito, M., McGready, R., Tinto, H., Rouamba, T., Mosha, D., Rulisa, S., Kariuki, S., Desai, M., Manyando, C., Njunju, E. M., Sevene, E., Vala, A., Augusto, O., Clerk, C., Were, E., Mrema, S., Kisinza, W., Byamugisha, J., Kagawa, M.,... Dellicour, S. (2023). Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus nonartemisinin antimalarials: A systematic review and individual patient data meta-analysis. Lancet, 401(10371), 118–130. https://doi.org/10.1016/S0140- 6736(22)01881-5

[30] Radeva-Petrova, D., Kayentao, K., Ter Kuile, F. O., Sinclair, D., & Garner, P. (2014). Drugs for preventing malaria in pregnant women in endemic areas: Any drug regimen versus placebo or no treatment. Cochrane Infectious Diseases Group, editor. Cochrane Database of Systematic Reviews. http: //doi.wiley.com/10.1002/14651858.CD000169.pub3 https://doi.org/10.1002/14651858.CD000169.pub3

[31] Gutman, J., Van Eijk, A., Rodriguez, E., Ahn, J., & Ter Kuile, F. (2022). Sulfadoxine-pyrimethamine resistance and intermittent preventive treatment in pregnancy (IPTp) for the prevention of malaria in pregnancy: A systematic review and meta-analysis. Zenodo. https://zenodo.org/record/6559908

[32] Shibeshi, W., Alemkere, G., Mulu, A., & Engidawork, E. (2021). Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: A systematic review and meta-analysis. BMC Infectious Diseases, 21(1), 326. https://doi.org/10.1186/s12879-021-06018-6

[33] Assefa, D. G., Zeleke, E. D., Bekele, D., Tesfahunei, H. A., Getachew, E., Joseph, M., & Manyazewal, T. (2021). Efficacy and safety of dihydroartemisininpiperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: A systematic review and meta-analysis of randomized control trials. Malaria Journal, 20(1), 174. https://doi.org/10.1186/ s12936-021-03711-4

[34] Sinclair, D., Donegan, S., Isba, R., & Lalloo, D. G. (2012). Artesunate versus quinine for treating severe malaria. Cochrane Infectious Diseases Group, editor. Cochrane Database of Systematic Reviews. https://doi.wiley.com/10.1002/ 14651858.CD005967.pub4 https://doi.org/10.1002/ 14651858.CD005967.pub4

[35] Pryce, J., Richardson, M., & Lengeler, C. (2018). Insecticide-treated nets for preventing malaria. Cochrane Infectious Diseases Group, editor. Cochrane Database of Systematic Reviews. https: //doi.wiley.com/10.1002/14651858.CD000363.pub3 https://doi.org/10.1002/14651858.CD000363.pub3

[36] Wangdi, K., Furuya-Kanamori, L., Clark, J., Barendregt, J. J., Gatton, M. L., Banwell, C., Kelly, G. C., Doi, S. A. R., & Clements, A. C. A. (2018). Comparative effectiveness of malaria prevention measures: A systematic review and network meta-analysis. Parasites & Vectors, 11(1), 210. https://doi.org/10.1186/s13071- 018-2783-y

[37] Yovogan, B., Sovi, A., Djènontin, A., Adoha, C. J., Akinro, B., Accrombessi, M., Dangbénon, E., Koukpo, C. Z., Affolabi, Z. K., Agboho, P. A., Kpanou, C. D., Assongba, L., Missihoun, A. A., Tokponnon, T. F., Agbangla, C., Padonou, G. G., Messenger, L. A., Ngufor, C., Cook, J.,... Protopopoff, N. (2024). The impact of pyrethroid-pyriproxyfen and pyrethroidchlorfenapyr long-lasting insecticidal nets on density of primary malaria vectors Anopheles gambiae s.s. and Anopheles coluzzii in Benin: A secondary analysis of a cluster randomised controlled trial. Parasites & Vectors, 17(1), 7. https://doi.org/10.1186/s13071-023- 06104-5

[38] Federal Ministry of Health. (2023). Malaria program review 2023. Federal Ministry of Health.

[39] Odoko, J. (2020). Primary healthcare on utilization of insecticide treated nets among pregnant mothers and carers of children in South –South Nigeria. Clinical Medical Reviews and Reports, 2(6), 01–06.